October 2014 placement according to CKD severity and (2) identify factors associated with death among patients with an ICD and CKD.
Methods

Data Sources
Data for this study were derived from the NCDR ICD Registry and the Social Security Death Master File. A collaboration of the Heart Rhythm Society and the American College of Cardiology Foundation, the NCDR ICD Registry was established in 2005 and became the only repository for ICD placement data for Medicare beneficiaries on April 1, 2006 . The Centers for Medicare and Medicaid Services mandate data input on its beneficiaries receiving a primary prevention ICD into this registry. Nonetheless, ≈78% of participating hospitals enter data on all ICD implantations irrespective of payer or indication. 19 These data include patient demographics, medical history, and clinical information, including preprocedure creatinine levels and whether patients are dialysis dependent. Vital status was available for patients via the Social Security Death Master file through December 31, 2009. Patients without a file during the study period were assumed alive. For patients with several device implants in the registry, the index implant was selected for the analysis.
Study Cohort
We selected patients who underwent primary prevention ICD placement and were discharged home alive between January 1, 2006, and December 31, 2007 . Patients with a history of myocardial infarction and a left ventricular ejection fraction ≤30% or a history of congestive heart failure with a left ventricular ejection fraction ≤35% were included. Patients with New York Heart Association class IV symptoms, a myocardial infarction within 40 days before implant or coronary artery bypass grafting within 90 days before implant, new-onset heart failure within 3 months of diagnosis, or inducible sustained ventricular tachycardia on electrophysiology study as the indication for device placement were excluded. Those receiving a biventricular device, or who were missing covariates necessary for determining eligibility for inclusion in this analysis, were also excluded.
Statistical Analysis
Glomerular filtration rate (GFR) was estimated from the preprocedure creatinine using the Chronic Kidney Disease Epidemiology Collaboration equation. 20 Baseline characteristics of patients with renal disease (estimated GFR, ≤60 mL/min per 1.73 m 2 ) were compared with those without renal disease (estimated GFR, >60 mL/min per 1.73 m 2 ). Continuous variables are presented as medians with 25th and 75th percentiles, and categorical variables are presented as percentages and counts. Differences between groups were assessed using the Wilcoxon rank-sum test and Pearson χ 2 test as appropriate. Patients were then categorized according to GFR and whether they were dialysis dependent: >60, 30 to 60, and <30 mL/min per 1.73 m 2 but not on dialysis, and dialysis dependent. Unadjusted event rates of death and in-hospital complications and comparisons were identified for various levels of renal function. Unadjusted Kaplan-Meier 1-and 3-year all-cause death rates and corresponding curves of cumulative risk of death were generated for each renal function group. An unadjusted Cox proportional hazards model was used to test for a difference between the group without renal disease and each of the other 3 groups. As our primary interest was in assessing death risk among patients with CKD, we examined whether the relationship between candidate predictors and death risk varied with renal function, by testing interactions between each variable and the presence or absence of CKD, one at a time in otherwise unadjusted models. The substantial number of significant interactions indicated that explanation of death risk among patients with CKD might be considerably different than among patients without CKD, and that development of the model in the subgroup of patients with CKD was warranted. A multivariable Cox proportional hazards model assessing the impact of renal disease among those with an estimated GFR <60 mL/min per 1.73 m 2 was then fitted. The linearity of continuous variables' relationships to death was assessed, and cubic-polynomial splines were used as needed. For candidate predictors in the model, missing data were imputed to the median for continuous variables and the mode for categorical variables. Rates of missingness were <1% for any variable under consideration. We performed a sensitivity analysis in which patients were weighted by the inverse of their propensity to have missing covariates, 21 to confirm that the simple imputation method did not introduce bias; results from this analysis were similar to the original analysis. Covariates were entered into the model using forward stepwise selection. Renal disease terms were retained in the model regardless of their significance. The proportional hazards assumption for 3 major covariates that might be expected to violate the assumptionage, sex, and renal disease group-was tested using a stratified multivariable Cox model with those 3 covariates as strata; there were no substantive changes in estimated hazard ratios (HRs) and 95% confidence intervals (CIs).
Results are presented as HRs and 95% CIs, and an α level of 0.05 was used for statistical significance. All analyses were performed using SAS version 9.2 (SAS Institute Inc, Cary, NC). The Duke University Health System institutional review board approved the study and determined that informed consent was not applicable to data collected by the ICD Registry.
Results
After applying our exclusion criteria, the final study cohort consisted of 47 282 patients from 1134 sites. Compared with patients without CKD disease, those with CKD disease were older, less commonly men, more often white, and more frequently covered by Medicare (Table 1) . They had more advanced heart failure symptoms and more frequently had other comorbid illness, including atrial fibrillation or flutter, abnormal sinus node function, ischemic heart disease and prior revascularization, cerebrovascular disease, diabetes mellitus, and hypertension. They also more commonly had electrocardiographic abnormalities, including a wide QRS complex, left bundle-branch block, and atrioventricular conduction delay.
Patients with advanced CKD had higher rates of hematoma after ICD placement but not lead dislodgement, pneumothorax, cardiac perforation, or pericardial tamponade ( Table 2) . After a median follow-up of 2.9 years, 9676 patients (20.5%) died. Death rates varied according to the CKD severity ( Table 2) . Compared with patients without CKD, patients with a GFR 30 to 60, GFR <30, and end-stage renal disease on dialysis had a higher risk of death after ICD placement (HR, 2.08; 95% CI, 1.99-2.18; P<0.0001; HR, 4.20; 95% CI, 3.92-4.50; P<0.0001; and HR, 4.80; 95% CI, 4.46-5.17; P<0.0001, respectively). One-year unadjusted Kaplan-Meier death rates among patients without CKD and the aforementioned CKD categories were 4.4%, 9.1%, 20.2%, and 22.4%, respectively ( Table 2 ). Approximately 1 in 2 patients with a GFR <30 or on dialysis died within 3 years of ICD placement. The cumulative risk of death among patients with mild CKD (GFR, 30-60) diverged from that of patients without CKD immediately after ICD placement (Figure) . The greater cumulative risk of death among patients on dialysis compared with those with advanced CKD (GFR <30) was evident by 6 months after ICD placement.
Among patients with CKD, factors most strongly associated with risk of death were severity of CKD (end-stage renal disease on dialysis versus GFR, 30- (Table 3 ).
Discussion
This is the largest study to examine the survival pattern of patients with CKD with a primary prevention ICD as well as factors associated with survival. It has 3 major findings. First, the risk of death after ICD placement varied according to the severity of CKD. Patients with end-stage renal disease on dialysis have the worst prognosis; however, even mild reductions in GFR are associated with a significant reduction in survival. Second, compared with patients without CKD, those with CKD have a greater burden of comorbid illness and thus are more predisposed to comorbidity-related death. Third, in addition to CKD severity, several other factors are associated with a higher risk of death among patients with CKD with an ICD, including older age, the degree of heart failure symptoms, and diabetes mellitus. A secondary evaluation of the Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) indicated that the ICD was not beneficial among patients with an estimated GFR <35 mL/min per 1.73 m 2 (all-cause death HR, 1.09; P=0.84). 22 A subgroup analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) found that the ICD was less effective among patients with a GFR <60 compared with those with a higher GFR (HR, 0.74; 95% CI, 0.39-1.39 versus HR, 0.27; 95% CI, 0.16-0.46; difference P=0.011). 23 A meta-analysis of the MADIT-I, the MADIT-II, and the SCD-HeFT indicates that ICD efficacy varies according to GFR. 24 ICD placement may not significantly alter the natural course of these patients. CKD per se or associated comorbidities may predispose patients to death. Arrhythmic death refractory to defibrillation such as that associated with acute metabolic disarray 25 or competing causes of nonarrhythmic death such as pump-failure 7 may play significant roles in this regard. In the absence of further studies, professional guidelines do not explicitly address the role of CKD in the selection of ICD candidates. They nonetheless specify that recipients should have an estimated life expectancy of ≥1 year. 18 Our findings indicate that CKD, even in its most advanced form, is not a strict contraindication to ICD placement based on this criterion.
Figure.
Cumulative risk of death by severity of chronic kidney disease. The risk of death among patients with mild kidney disease (glomerular filtration rate [GFR], 30-60) differed from that of patients without kidney disease (GFR, >60) immediately after placement of a primary prevention implantable cardioverter-defibrillator. A higher risk of death among patients on dialysis compared with those with advanced chronic kidney disease (GFR,<30) was evident by 6 months after device placement. However, among patients with a GFR <30, ≈1 in 5 died by 1 year and 1 in 2 by 3 years after ICD placement. Factors associated with survival in our analysis, including older age, the degree of heart failure symptoms, and diabetes mellitus among others, may in fact aid in the selection of candidates most likely to derive a survival benefit from an ICD. CKD is associated with a higher risk of in-hospital complications after ICD placement. 26 The current analysis indicates the most clinically relevant in-hospital complication ICD recipients with CKD experience is hematoma, and this is largely limited to those with advanced disease.
It is noteworthy that a prior NCDR analysis examined patients with CKD; however, that analysis was restricted to end-stage renal disease and only examined in-hospital outcomes. 27 Previous studies of patients in various stages of CKD were performed in 1 or 2 centers and limited by modest sample sizes. [13] [14] [15] [16] [17] The current analysis characterizes the association between CKD severity and long-term survival on a national scale with a considerable degree of granularity, identifies additional factors associated with death not previously observed in this patient subgroup, and extends the findings to an expansive population of 1134 sites.
Implications of the current analysis are clear. Life expectancy after ICD placement among patients with a GFR <30 irrespective of whether dialysis has been initiated is sufficiently limited to give patients and physicians pause before proceeding with placement, particularly because these patients are also predisposed to procedural risk 11, 27 and infection. A comparison group of ICD nonrecipients was not included in the current analysis. The observed mortality rates are nonetheless comparable with those of high-risk patients with multiple comorbidities unlikely to benefit from an ICD. 28, 29 Discussions between physicians and patients on the potential benefits of the ICD that take into account clinical factors associated with death and competing causes of death may be worthwhile before proceeding with placement. However, the efficacy, effectiveness, and cost-effectiveness of ICD therapy in this patient subgroup remain unknown. Further study in each of these areas is required.
Limitations
The current analysis has several limitations. First, CKD staging for nondialysis patients was based on creatinine levels obtained just before ICD placement, and they might not reflect steady-state levels. However, it is expected that because these implants are elective, most creatinine values were at or close to baseline. Second, participation in the ICD Registry is mandatory for ICD recipients with Medicare and thus our findings may not be generalized to other patient populations. However, the majority of participating hospitals enter data on all implantations regardless of insurance, and 38% of the patients in the current analysis had non-Medicare insurance. The NCDR ICD Registry data are susceptible to data entry errors. However, periodic audits suggest that >90% of fields accurately reflect the data in medical charts. 30 Finally, our analyses were observational and thus subject to residual and unmeasured confounding.
Conclusions
The risk of death after ICD placement is proportional to CKD severity. Patients with CKD have a higher burden of comorbidities than those without CKD. Consequently, they are more predisposed to comorbidity-related death. Among patients with CKD, several factors are prognostically significant, including CKD severity, older age, the degree of heart failure symptoms, and diabetes mellitus. Further studies on the efficacy, effectiveness, and cost-effectiveness of ICD therapy among patients with CKD, particularly those with advanced disease, are needed.
